This laboratory assay detects IgG autoantibodies specific to mGluR5, a receptor expressed on neurons, especially within the limbic system and hippocampus. Metabotropic glutamate receptors (mGluRs) are G-protein–coupled receptors activated by glutamate, the main excitatory neurotransmitter in the CNS. There are eight mGluR subtypes (mGluR1–8) classified into three groups by their molecular, pharmacologic and signalling properties. mGluR5 and mGluR1 belong to Group I, are predominantly postsynaptic, and are involved in learning, memory, epilepsy and pain. Autoantibodies to these receptors are linked to several autoimmune CNS disorders.
Anti-mGluR5 antibodies are found in a distinct form of autoimmune limbic encephalitis known as Ophelia syndrome, often featuring behavioural and cognitive disturbances and associated with Hodgkin lymphoma in about half of cases. Typical manifestations include personality and behavioural changes, memory and attention deficits, and sometimes seizures or status epilepticus. In more severe cases, altered consciousness and hypoventilation may occur. Early diagnosis and immunosuppressive therapy can lead to partial or complete remission in most cases.
Serum, plasma, CSF
IFA cells
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.